FDA Clears Legend Biotech's LB2501 CAR — T Therapy for Clinical Trials

Legend Biotech received FDA clearance for its investigational new drug application for LB2501, a dual-targeting CD19/CD20 in vivo CAR-T therapy. The clearance supports a planned US Phase 1/2 trial in relapsed or refractory B-cell malignancies. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Legend Biotech Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001171843-26-006646), on October 15, 2026, and is solely responsible for the information contained therein. (C)